
VaxGen developed the first vaccine against smallpox in over 30 years, which was licensed to Aventis Pasteur in 2002.
This achievement marked a significant milestone in the fight against smallpox, a disease that had been eradicated but still posed a threat due to the potential for bioterrorism.
The smallpox vaccine was just one of the many life-saving vaccines developed by VaxGen, which also worked on an AIDS vaccine.
VaxGen's expertise in vaccine development and production made them a valuable partner in the global effort to combat infectious diseases.
VaxGen Vaccines
VaxGen had focused its efforts on developing an anthrax vaccine, for which it was awarded a massive $877 million contract in 2006.
The company's work on the anthrax vaccine was significant, but its stock price plummeted when the contract was unilaterally withdrawn by the US Department of Health and Human Services in December 2006, sending the stock tumbling as low as $1.20 per share.
A different take: Smart Contract Development Company
In addition to the anthrax vaccine, VaxGen had also been working on a safer smallpox vaccine, which it acquired from a Japanese company, Chemo-Sero-Therapeutic Research Institute (Kaketsuken).
The smallpox vaccines could still be produced at VaxGen's San Francisco plant, offering a glimmer of hope for the company's vaccine efforts.
VaxGen's work on an AIDS vaccine, called AIDSVAX, was also notable, with the company conducting large-scale trials involving 5,000 volunteers in North America and Thailand by 1998.
Smallpox and AIDS Vaccines
VaxGen developed an AIDS vaccine candidate, a protein called gp120, but it failed in Phase III clinical trials and provided no protection.
In the 1990s, VaxGen developed an AIDS vaccine called AIDSVAX, which was a three-year large-scale trial involving 5,000 volunteers at about 40 clinical sites in North America.
The National Institute of Allergy and Infectious Diseases (NIAID) worked with Vaxgen on research projects related to the body's immune response to AIDSVAX.

Dr. Anthony Fauci described the effort to develop a safe and effective vaccine against HIV/AIDS as a global imperative and the highest priority of the NIH AIDS research program.
VaxGen also acquired the rights to a safer smallpox vaccine from the Chemo-Sero-Therapeutic Research Institute (Kaketsuken), a Japanese company, which could still be produced at the San Francisco plant.
A unique perspective: BCA Research
Anthrax Vaccine
VaxGen had a major focus on developing an anthrax vaccine, for which it was awarded a massive $877 million contract in 2006.
This contract was part of the Project Bioshield Act, a significant government initiative aimed at developing and procuring medical countermeasures against bioterrorism threats.
The contract was abruptly withdrawn by the United States Department of Health and Human Services (HHS) in December 2006, causing the company's stock to plummet as low as $1.20 per share.
The withdrawal of the contract was a devastating blow to VaxGen, highlighting the risks and uncertainties involved in developing and commercializing vaccines.
The company's anthrax vaccine candidate was supposed to be delivered in large quantities, with 25 million doses intended for the stockpile by the end of 2007.
Company News

VaxGen, a biotechnology company, was founded in 1996. It was a publicly traded company listed on the NASDAQ stock exchange.
The company's headquarters was located in Brisbane, California, and it had a research and development facility in Rockville, Maryland.
VaxGen's focus was on developing vaccines and other biopharmaceutical products. The company's pipeline included several promising candidates.
One of its notable projects was the development of a vaccine for anthrax, which was a major public health concern at the time.
Vaccine Effectiveness
VaxGen's anthrax vaccine was a major focus for the company, with a $877 million contract from the US government under the Project Bioshield Act. This contract was a significant milestone for the company.
However, the contract was unilaterally withdrawn by the US Department of Health and Human Services in December 2006, causing the stock price to plummet. The company's stock price dropped as low as $1.20 per share.
VaxGen also had a candidate for an AIDS vaccine, but it failed to provide protection in Phase III clinical trials. This was a significant setback for the company.
Despite this failure, VaxGen acquired the rights to a safer smallpox vaccine from a Japanese company, Kaketsuken. This vaccine could still be produced at the company's San Francisco plant.
Intriguing read: Regions Financial Corporation Stock Price
Featured Images: pexels.com
